Lazertinib Mesylate

CHEMBL6068478 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

668.8 g/mol

LogP

—

Phase

4

A mesylate salt form of lazertinib, a third-generation EGFR inhibitor used to treat EGFR-mutated non-small cell lung cancer, formulated to improve solubility and absorption.

Molekularmasse

668,8000 g/mol

TPSA

173,00 Å²

Wirkmechanismus

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer …

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

C=CC(=O)Nc1cc(Nc2nccc(-n3cc(CN(C)C)c(-c4ccccc4)n3)n2)c(OC)cc1N1CCOCC1.CS(=O)(=O)O.O

InChI

InChI=1S/C30H34N8O3.CH4O3S.H2O/c1-5-28(39)32-23-17-24(26(40-4)18-25(23)37-13-15-41-16-14-37)33-30-31-12-11-27(34-30)38-20-22(19-36(2)3)29(35-38)21-9-7-6-8-10-21;1-5(2,3)4;/h5-12,17-18,20H,1,13-16,19H2,2-4H3,(H,32,39)(H,31,33,34);1H3,(H,2,3,4);1H2

Molecular Formula

C31H40N8O7S

HBD / HBA

4 / 13

Rotierbare Bindungen

10

Schwere Atome

47

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A mesylate salt form of lazertinib, a third-generation EGFR inhibitor used to treat EGFR-mutated non-small cell lung cancer, formulated to improve solubility and absorption.

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Yes, Lazertinib Mesylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL6068478. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 163203547. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Lazertinib Mesylate auf PillFYI

Struktur

Schnelldaten

Formel: C31H40N8O7S

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.